Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet medical needs in rare diseases by using precision medicine approaches. We are working on several disease areas that include HDV infection, chylomicronemia syndrome (patients with extremely high triglyceride levels and suffering from frequent pancreatitis), as well as rare kidney diseases such as IgA nephropathy. We also have our own clinical trial unit specialized for clinical phase 2 studies. All Ribocure staff are located in the GoCo Clinic building, GoCo Health Innovation City in Mölndal, Sweden.

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
July 22, 2026 · Shanghai, China and Molndal, Sweden Suzhou

